Treatment using anti-TIGIT antibodies and PD-1 axis binding antagonists

The present invention relates to the treatment of esophageal cancer, such as esophageal squamous cell carcinoma (ESCC) (e.g., advanced ESCC (e.g., non-resectable, locally advanced, recurrent and or metastatic ESCC)). More specifically, the present invention relates to the treatment of patients with esophageal cancer by administering an anti-T cell immune receptor (TIGIT) antagonist antibody having Ig and ITIM domains in combination with a Programmed Death-1 (PD-1) axis binding antagonist. 本发明涉及食管癌例如食管鳞状细胞癌(ESCC)(例如，晚期ESCC(例如，不可切除的、局部晚期、复发性和或转移性ESCC))的治疗。更具体地，本发明涉及通过施用具有Ig和ITIM结构域的抗T细胞免疫受体(TIGIT)拮抗剂抗体与程序性死亡-1(PD-1)轴结合拮抗剂的组合来治疗患有食管癌的患者。